DSpace at RU >

Search Results

Results 1-16 of 16.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2011	Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab	Lumig, P.P.M. van; Driessen, R.J.B.; Roelofs-Thijssen, M.A.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2011	Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists	Vries, H.S. de; Oijen, M.G.H. van; Driessen, R.J.B.; Jong, E.M. de; Creemers, M.C.W.; Kievit, W.; Jong, D.J. de
	2010	Effects and side effects of biological treatment for severe psoriasis in daily practice.	Driessen, R.J.B.
	2010	Daily practice assessment of liver injury in patients with psoriasis on methotrexate.	Driessen, R.J.B.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2010	Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.	Driessen, R.J.B.; Jong, E.M.G.J. de; Salemink, G.W.; Burer, J.H.G.; Kerkhof, P.C.M. van de; Hoogen, F.H.J. van den
	2010	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.	Lumig, P.P.M. van; Lecluse, L.L.; Driessen, R.J.B.; Spuls, P.I.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2010	The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics.	Driessen, R.J.B.; Bisschops, Laurens; Adang, E.M.M.; Evers, A.W.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2010	Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.	Lecluse, L.L.; Driessen, R.J.B.; Spuls, P.I.; Jong, E.M.G.J. de; Stapel, S.O.; Doorn, M.B. van; Bos, J.D.; Wolbink, G.J.
	2009	Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement	Lingen, R.G. van; Erp, P.E.J. van; Seyger, M.M.B.; Jong, E.M.G.J. de; Boer-van Huizen, R.T. de; Driessen, R.J.B.; Kerkhof, P.C.M. van de
	2009	Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.	Driessen, R.J.B.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2009	Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.	Driessen, R.J.B.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2008	Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis.	Driessen, R.J.B.; Jong, E.M.G.J. de; Rie, M.A. de; Salemink, G.W.; Kerkhof, P.C.M. van de
	2008	Etanercept combined with methotrexate for high-need psoriasis.	Driessen, R.J.B.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2008	Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.	Driessen, R.J.B.; Berends, M.A.M.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2007	Biologicals in de praktijk : prospectieve cohortmonitoring van high need psoriasispatiënten	Driessen, R.J.B.; Berends, M.A.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
	2007	Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.	Berends, M.A.M.; Driessen, R.J.B.; Langewouters, A.M.G.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de

1